Please assess the completion status of the following clinical trial:

Trial Title: Effects of GnRHa on Ovarian Function Against Chemotherapy-induced-gonadotoxicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Premenopausal women 18 to 49 years of age are eligible for enrollment~* Patients have operable stage I to IIIA breast cancer for which treatment with adjuvant or neoadjuvant cyclophosphamide-containing chemotherapy was planned.~* Eligible participants had taken no estrogens, antiestrogens, selective estrogen-receptor modulators, aromatase inhibitors, or hormonal contraceptives within the month before enrollment.~* Human chorionic gonadotropin negative by urine test before entering the group.~* Informed consent, understanding and compliance with the requirements of the study.~* No significant chronic disease and any organ dysfunction.~Exclusion Criteria:~* Exceptions were made for the use of hormonal contraception in women younger than 35 years of age that was discontinued before randomization.~* Use of hormonal treatment for up to 2 months for the purposes of in vitro fertilization and cryopreservation of embryos or oocytes before randomization.~* Patients with metastatic lesions or history of bilateral ovariectomy,ovarian radiation were excluded.~* Patients received previous adjuvant endocrine therapy for breast cancer are not suitable to this trial.~* Patients with uterine and/or adnexal diseases needing medical or surgical treatment are not suitable.~* Allergic to active or inactive excipients of GnRHa is an exclusion criterion.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- GnRHa group (Type: EXPERIMENTAL): Eligible patients with breast cancer treated with GnRHa while receiving chemotherapy.
- None GnRHa group (Type: NO_INTERVENTION): Eligible patients with breast cancer treated without GnRHa while receiving chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).